Through a series of functional studies conducted both in vivo and in vitro, we demonstrated in our study that the PRMT5–meR316-ALKBH5–CD276 axis promotes CRC carcinogenesis and revealed that meR316-ALKBH5 expression in CRC affects tumor immune evasion. Here, CD276 is linked to neoplasm.